Cryoport provides cutting-edge frozen shipping services to the life sciences industry. It does so through a combination of purpose-built proprietary technologies and total turnkey management of the entire logistics process. The company’s service management approach offers reliability, cost effectiveness, and convenience.
The company announced today that it appointed Richard G. Rathmann to Cryoport’s Board of Directors. With this addition to its Board, Cryoport now consists of five members, four of which are independent, including Mr. Rathmann.
Mr. Rathmann is an experienced venture fund manager and advisor to life science companies. He is currently the manager of GBR Investments LLC and also serves as director of Cellerant Therapeutics and executive director of the Rathmann Family Foundation. Earlier in his career, Rathmann co-managed the early stage venture fund Falcon Technology Partners L.P. This fund was a seed investor in companies including Adolor, Caliper, deCode, Genomica, and Ciphergen/Vermillion.
Mr. Rathmann is highly regarded in the life science industry, which should be an aid to Cryoport. He will be able to provide the company with insights into the needs of potential customers across various industry sectors. Rathmann himself said that he sees in Cryoport “many attributes of companies he helped fund at an early stage that later went on to create tremendous value” for shareholders.
For further information about Cryoport and its unique frozen shipping solutions for the life science industry, visit www.cryoport.com
Let us hear your thoughts below: